PipelineReview.com6d
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 ― ...
PipelineReview.com6d
HotSpot Therapeutics Presents First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024
BOSTON, MA, USA I 12, 2024 I HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule ...
PipelineReview.com6d
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile ...
PipelineReview.com6d
Nona Biosciences Enters into Collaboration Agreement with Umoja Biopharma to Advance In Vivo CAR-T Cell Therapies
CAMBRIDGE, MA, USA I 12, 2024 I Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), announced ...
PipelineReview.com6d
Kriya Highlights Positive Preclinical Data for KRIYA-586, a Gene Therapy Product Candidate for Thyroid Eye Disease (TED), at ESOPRS Annual Meeting
Preclinical data demonstrate pharmacodynamic activity of KRIYA-586, an investigational gene therapy which encodes for an anti-IGF1R antibody – ...
PipelineReview.com6d
Kine Sciences Announces First Patient Dosed in the Phase 1b/2a Study in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
SEOUL, South Korea I 13, 2024 I Kine Sciences, a clinical-stage, biopharmaceutical company developing small peptides for immune-mediated ...
PipelineReview.com9h
Transcenta Updates Encouraging Efficacy Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024
PRINCETON, NJ, USA and SUZHOU, China I September 18, 2024 I Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated ...
PipelineReview.com11h
4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day
EMERYVILLE, CA, USA I September 18, 2024 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company ...
PipelineReview.com11h
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household members – ...
PipelineReview.com1d
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional ...
PipelineReview.com1d
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
EAST HANOVER, NJ, USA I 17, 2024 I Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali® (ribociclib) in ...
PipelineReview.com1d
Nexilico and Siolta Therapeutics Enter Collaboration Agreement to Develop a Novel Microbiome Therapeutic for Necrotizing Enterocolitis
DANVILLE, CA, USA I September 17, 2024 I Nexilico, a pioneer in precision microbiome engineering, and Siolta Therapeutics, a leader in the development of live ...